A fifty-four-year-old chief executive in Maitama has been on metformin for two years for pre-diabetes that became Type 2, on a low-dose statin for an LDL that crept up despite three honest attempts at "eating better," and on intermittent sildenafil from the only pharmacist he trusts in Wuse for the erectile dysfunction he has now finally accepted is not going away. His annual physical this April returned a lipid profile that is worse than last year's, an HbA1c that has drifted from 6.7 to 7.2 despite the medication, and a fasting insulin that, when his physician finally orders it, is clinically elevated. He is doing everything his GP has told him to do. He is also not getting better.
There is a single intervention that reverses, simultaneously and through the same biological mechanism, all three of the conditions he is currently being treated for symptomatically. The intervention is not a new drug. It is not coming out of a pharma pipeline. It is not waiting on a clinical trial. It has Grade A evidence behind it, sits in the first line of multiple international guidelines, and is, on a per-outcome basis, more effective than every pill in his current regimen. He is not being prescribed it because the prescription is uncomfortable. It requires him to lift weights three times a week, and to continue doing so for the rest of his life.
He prefers the four pills.
This is the third and final piece in the short series this blog has been running on the silent epidemics in Nigerian men's health. The first was about erectile dysfunction as the cardiovascular warning most men self-medicate past. The second was about the two bottles — the energy drink and the agbo — quietly killing Nigerian men's kidneys and livers. Both pieces were about damage being received, ignored, and accelerated. This piece is about the intervention that actually defeats the underlying disease — and about why, despite that intervention being free, available, and clinically decisive, the Nigerian executive demographic that most needs it is the one demographic that almost never takes it.
What lifting weights actually does, biologically
The cultural framing of resistance training in Nigeria is almost entirely cosmetic. The young man at the gym in Wuse 2 is understood to be training for aesthetics. The professional footballer is training for performance. The middle-aged Nigerian executive is understood not to belong in the room. That cultural framing is the most expensive misunderstanding in Nigerian men's medicine, because the biological effects of resistance training are the opposite of cosmetic. They are cardiometabolic, vascular, and hormonal, and they are the effects most directly relevant to the diseases the executive is paying for prescriptions to manage.
Skeletal muscle is the body's largest organ by mass and its largest insulin sink by a significant margin. Roughly seventy to eighty percent of an insulin-mediated glucose load is disposed of through skeletal muscle. Resistance training increases the density of insulin-responsive GLUT4 transporters on muscle cell membranes, increases mitochondrial density inside those cells, and enlarges the actual physical volume of the disposal sink — which means a given dose of insulin moves more glucose, and the pancreas is required to secrete less of it to maintain the same blood-sugar level. The man with rising insulin resistance is, in mechanical terms, a man whose disposal sink has been shrinking by roughly half a percent a year since his late twenties. Resistance training reverses that shrinkage. The metformin compensates for the smaller sink. The lifting rebuilds it.
The endothelial nitric-oxide pathway — the same pathway whose failure produces the early erectile dysfunction described in the first piece in this series — is upregulated by chronic exercise, and specifically by exercise that produces meaningful skeletal-muscle adaptation. The mechanism is well characterised. Exercise increases shear stress on the endothelium. Shear stress upregulates endothelial nitric oxide synthase. Nitric oxide production increases. Vasodilation improves. The vascular bed becomes more responsive. Erections become more reliable, blood pressure becomes more controllable, and the cardiac muscle that is itself dependent on a healthy endothelium gets a better blood supply. The man who lifts is, slowly, repairing the same biology that the sildenafil from the Wuse pharmacist is only temporarily bypassing.
Endogenous testosterone, which falls with metabolic dysfunction and falls again with sarcopenia, is also responsive to resistance training. The lift-induced rise in testosterone is not large, and it is not the same biology as an injected testosterone replacement, but it is the appropriate biology for a man whose levels have drifted from normal-young into low-middle-aged because his muscle mass has been quietly atrophying. Restoring the muscle restores some of the hormonal pattern. The same intervention raises the body's anabolic tone, lowers cortisol, improves sleep architecture, improves mood, and decreases the inflammatory markers that quietly accelerate everything else.
And underneath all of that is sarcopenia itself — the gradual loss of muscle mass that begins in the thirties and accelerates through the forties, fifties, and sixties. Sarcopenia is one of the most reliable predictors of all-cause mortality in middle age that almost nobody is screened for. Grip strength alone, measured with a cheap dynamometer in the office, predicts mortality with comparable resolution to cholesterol and blood pressure in men over fifty. The lift fights the sarcopenia directly, and through it, fights everything sarcopenia drives.
The evidence base — this is not lifestyle advice. It is medicine.
The standard treatment of exercise in Nigerian primary care is as a piece of advice given near the end of a consultation about something else. Try to exercise more. The standard treatment of exercise in current international cardiometabolic medicine is as a prescription with a specific dose, a specific protocol, and a measurable outcome. The difference between those two treatments is the difference between a casual encouragement and a clinical intervention.
The evidence supporting the prescription is now substantial enough that it has reshaped the relevant guidelines. The DiRECT trial showed that a structured lifestyle intervention, weighted heavily toward nutrition but with a meaningful exercise component, achieved Type 2 diabetes remission in roughly half of participants at twelve months and roughly a third at two years — remission, not management, not "well controlled," but the absence of the diagnostic criteria for the disease. The ACSM and ADA joint position statement on exercise and Type 2 diabetes places resistance training, performed at least twice a week, as a first-line component of treatment alongside aerobic exercise. The European Society of Cardiology's prevention guidelines now include explicit dosing for both aerobic and resistance training for cardiovascular risk reduction.
The evidence specifically connecting exercise to erectile dysfunction reversal is also substantial. Multiple randomised controlled trials, including pooled analyses, have shown that supervised aerobic and resistance training programmes produce ED improvement comparable in magnitude to PDE5 inhibitors — with the difference that the underlying disease, not just the symptom, is being addressed. In some trials, the patients on the exercise protocol no longer required the pill at the end of the intervention. Their endothelial function had recovered enough that the pharmaceutical assist was no longer needed.
What this means in plain language is that the chief executive on the four prescriptions has, if he chooses, access to a treatment that is more effective than the prescriptions at addressing the underlying disease, and that may, over time, allow him to come off some of the prescriptions entirely. The treatment is harder than swallowing pills. That is the only material disadvantage it carries.
Why the Nigerian executive specifically isn't doing it
This is the part of the conversation that the international literature does not have to have. In Helsinki and Toronto, middle-aged executives lift weights. In Tokyo and Singapore, they lift weights. In Lagos and Abuja, with rare exception, they do not. The cultural reasons for that are specific, and they are worth naming because they are surmountable once named.
The dominant gym narrative in Nigeria is vanity. Going to the gym is read, by both the man considering it and the people around him, as either a young man's pursuit of aesthetics or a middle-aged man's slightly embarrassing attempt to be younger than he is. Neither framing has anything to do with metabolic disease. Both make it socially harder for a senior man with no aesthetic ambition to walk into a gym and lift seriously.
The dominant exercise norm in the Nigerian executive demographic is walking and, for the more committed, jogging. Both are useful. Neither is sufficient. Walking and jogging are predominantly aerobic, predominantly low-intensity, and have weak effects on muscle mass, on grip strength, on bone density, on insulin sensitivity beyond what aerobic exercise alone delivers. The man who jogs at six in the morning four times a week is doing something genuinely good, and is also doing something less than half of what his metabolic situation actually requires. The remaining half is the resistance work, and it is the half almost nobody in the demographic does.
The advice from the primary-care physician is, in most cases, vague. You should try to exercise more. This is not a prescription. A prescription is three sessions per week, sixty to seventy-five minutes each, compound movements — squat, deadlift, bench press, overhead press, row — at a weight you can complete eight to twelve repetitions of with the last two being genuinely difficult, progressing the load weekly when the protocol allows it, supervised by a competent coach for the first three months, with grip strength and lean body mass reassessed at six months. The first formulation produces no change in behaviour. The second formulation, when delivered in a relationship that earns compliance, changes the patient's biology over a year.
The infrastructure for the second formulation does exist in Abuja and Lagos. There are serious gyms. There are competent strength coaches. There are domestic home setups that fit comfortably in a Maitama or Ikoyi residence. The barrier is not the equipment. The barrier is that nobody is writing the prescription, nobody is following up on it, and the patient is therefore left to navigate a vague encouragement on his own — which, predictably, he does not.
What concierge medicine catches and prescribes
A serious annual physical for a male member over forty contains, in our practice, several components that the standard Nigerian physical does not. A grip-strength measurement using a dynamometer, scored against age-adjusted normals. A lean-body-mass estimate by bioelectrical impedance, tracked year on year. A fasting insulin alongside the HbA1c, so that the disposal sink can be inferred and not just the glucose. A morning testosterone if clinically indicated. These are not exotic tests. They are cheap, fast, and revealing. They are not run by default because nobody is reading them serially against the patient's own prior values, and because the conversation they enable — the one where a fifty-four-year-old man is told, in clear language, that his grip strength is in the bottom quartile for his age and that this is a clinical finding, not a moral one — is a conversation default care does not have time for.
When the conversation is had, the prescription that follows is specific. Three sessions a week. Sixty to seventy-five minutes. Compound lifts. Eight to twelve repetitions per set. Progressive load. Supervised by a coach we know, with credentials we can vouch for, who has worked with men in this demographic before and will not treat the patient like a twenty-three-year-old aspiring bodybuilder. Reassessed at three months and again at six months on the same biomarkers that diagnosed the problem in the first place. Where appropriate — and this is the part of the conversation that most pleases the patient — pharmaceutical deprescribing as the markers improve. The metformin dose reduced as the HbA1c falls. The statin reviewed as the lipid profile normalises. The sildenafil left in the drawer because it is no longer reliably needed.
A note on the statin in particular is worth adding, because the prescription itself is in active academic dispute. A serious and currently unresolved debate has run for several years now over whether statins are appropriate in primary prevention in lower-risk patients — sustained in the UK by critics including the cardiologist Aseem Malhotra and a series of BMJ editorials questioning the harm-benefit balance, and supported underneath by mechanistic concerns about statin effects on mitochondrial coenzyme Q10 in cardiac muscle. That argument is its own piece, and we are not making it here. The narrower point in this one is that the man whose insulin resistance and endothelial function are recovering may, in close conversation with his physician, find that the statin question itself becomes a less urgent one — because his lipid profile is no longer asking it in the same way.
There is a version of medicine where the prescription is the drug that manages the symptom while the underlying disease worsens. That is the version most Nigerian men are currently on. There is another version where the prescription is the intervention that addresses the underlying disease while the symptom recedes. That version is more demanding, requires a relationship of some clinical seriousness between physician and patient, and produces, over the course of a year or two, a meaningfully different sixty-year-old.
Closing
The men this piece is written for have, in middle age, been quietly trained by every interaction with Nigerian healthcare to expect that the answer to most clinical problems is a pill, taken indefinitely, while the underlying biology drifts. The honest answer to most of those problems, in 2026, is not a pill. The honest answer is a structured behavioural intervention that the patient will resist, the family will mildly mock, and the physician will be tempted to soften into vague encouragement to avoid the resistance. The cost of the softened version is the chief executive on the four prescriptions whose lipid profile is worse this year than last.
If you are a man in your forties or fifties reading this, the most clinically valuable hour of your week for the next ten years is not the one with your physician. It is the one in which you are loading a barbell under competent supervision. The hour with the physician is what makes that possible — by getting the diagnosis right, by writing the prescription specifically, by following up on it, and by being honest with you when the markers are moving and when they are not.
That is what we do. The first conversation is private and costs nothing.